Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOR102 in Healthy Adults and Ulcerative Colitis
NCT06080048Phase 1Completed
- Sponsor
- Sorriso Pharmaceuticals
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- scFv Fragments, Bispecific Antibodies, Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of V56B2 in ulcerative colitis (UC) (3 arms), sponsored by Sorriso Pharmaceuticals. Primary endpoint: Treatment Emergent Adverse Events up to 6 weeks. Started Oct 2023; status: completed.
02
Drugs
V56B2
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06080048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06080048.